[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Contrast Agents/Media Global Market – Forecast To 2025

October 2018 | 415 pages | ID: C1B925D54B4EN
IQ4I Research & Consultancy Pvt. Ltd.

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Chemical substances that improve the visibility of specific organs, tissues or blood vessel during a diagnostic imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams makes use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of body are working and any associated abnormalities. Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of heart, liver and kidney.

As estimated by IQ4I Research, the contrast agent global market is expected to grow at single digit CAGR to reach $6,879.0 million by 2025. The contrast agent global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agent market held the largest market revenue in 2018 and microbubble segment is growing rapidly at double digit CAGR from 2018 to 2025 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agent market accounted the largest share. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that, they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted the largest share as they are safer and tolerable when compared to ionic contrast agent and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.

The contrast agents market by modality is segmented into X-Ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2018 and ultrasound segment is growing rapidly at double digit CAGR from 2018 to 2025 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include neck, liver and salivary gland imaging. Cardiovascular market accounted for the largest share and is the fastest growing market from 2018 to 2025 due to increase in a number of cardiac imaging procedures using Iodine, Gadolinium and microbubble contrast agents. Contrast agents market by route of administration is segmented into intravascular, oral, rectal and others which include intraosseous, intrathecal and intravesicle. Intravascular route of administration accounted for largest share and is the fastest growing market due to increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium and microbubble contrast agent to be administered intravascular.

Contrast agents market by imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging market held the largest market revenue and interventional imaging segment is growing at fast/rapidly at double digit CAGR from 2018 to 2025 due to increase in image guide procedures and increase in aging population who usually opt minimally invasive procedures.

Contrast agents market based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and other which include academic and research institutes. Hospitals market accounted largest share in 2018 as there is a rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers is the fastest growing segment with mid single digit CAGR from 2018 to 2025 due to increase in number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographical wise, North America region commanded the largest revenue in 2018. Favorable reimbursement coverage and increase in incidence and prevalence of diseases conditions due to change in lifestyle, obesity has led the market growth in this region. However, Asia-Pacific region is the second leading market for contrast agents and is expected to grow at mid single CAGR from 2018 to 2025 due to increased healthcare awareness, economic growth, large patient pool and rising aged population.

The contrast agent global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agent market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)
1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKEAWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
  2.6.1 MARKET SIZE ESTIMATION
  2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
  2.6.3 SECONDARY SOURCES
  2.6.4 PRIMARY SOURCES
  2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
  2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
  2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
  3.3.1 DRIVERS AND OPPORTUNITIES
    3.3.1.1 Increasing demand for diagnostic and interventional radiology procedures
    3.3.1.2 Increase in incidence and prevalence of disease conditions
    3.3.1.3 Increase in aging population
    3.3.1.4 Expansion in indications of contrast media market
    3.3.1.5 The growth of medical imaging technologies in emerging markets
    3.3.1.6 Increasing research activities for contrast agents
    3.3.1.7 Favorable reimbursement
  3.3.2 RESTRAINTS AND THREATS
    3.3.2.1 Side effect associated with contrast agents.
    3.3.2.2 Shortage of radiologist.
    3.3.2.3 Availability of alternative products
    3.3.2.4 Stringent regulations for contrast agents.
3.4 REGULATORY GUIDELINES
  3.4.1 UNITED STATES
  3.4.2 EUROPE
  3.4.3 CHINA
  3.4.4 JAPAN
  3.4.5 INDIA
3.5 REIMBURSEMENT SCENARIO
  3.5.1 REIMBURSEMENT TABLE
3.6 UPCOMING TECHNOLOGY
3.7 CLINICAL TRIALS
3.8 PATENT TRENDS
3.9 SUPPLY CHAIN ANALYSIS
3.10 PORTER’S FIVE FORCE ANALYSIS
  3.10.1 THREAT OF NEW ENTRANTS
  3.10.2 THREAT OF SUBSTITUTES
  3.10.3 BARGAINING POWER OF SUPPLIERS
  3.10.4 BARGAINING POWER OF BUYERS
  3.10.5 RIVALRY AMONG EXISTING COMPETITORS
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  3.11.1 CONTRAST AGENT GLOBAL MARKET
  3.11.2 X-RAY/CT CONTRAST AGENTS MARKET
  3.11.3 MRI CONTRAST AGENT MARKET
  3.11.4 ULTRASOUND BASED CONTRAST AGENT MARKET
3.12 CONTRAST AGENT GLOBAL CONSUMPTION

4 CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE

4.1 INTRODUCTION
4.2 IODINE BASED CONTRAST MEDIA
  4.2.1 IODINE BASED IONIC CONTRAST MEDIA
    4.2.1.1 Monomers
    4.2.1.2 Dimer
  4.2.2 IODINE BASED NON-IONIC CONTRAST MEDIA
    4.2.2.1 Monomer
    4.2.2.2 Dimer
4.3 GADOLINIUM-BASED CONTRAST MEDIA
  4.3.1 MACROCYCLIC
    4.3.1.1 Ionic
    4.3.1.2 Non-ionic
  4.3.2 LINEAR
    4.3.2.1 Ionic
    4.3.2.2 Non-ionic
4.4 MICROBUBBLE BASED CONTRAST MEDIA
4.5 OTHER CONTRAST MEDIA

5 CONTRAST AGENTS GLOBAL MARKET, BY MODALITY

5.1 INTRODUCTION
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT)
5.3 MAGNETIC RESONANCE IMAGING (MRI)
5.4 ULTRASOUND

6 CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION

6.1 INTRODUCTION
6.2 CARDIOVASCULAR
6.3 CANCER
6.4 GASTROINTESTINAL
6.5 MUSCULOSKELETAL
6.6 NEUROLOGY
6.7 NEPHROLOGY
6.8 OBSTETRICS AND GYNECOLOGY
6.9 UROLOGY
6.10 OTHERS

7 CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION

7.1 INTRODUCTION
7.2 INTRAVASCULAR
7.3 ORAL
7.4 RECTAL
7.5 OTHERS

8 CONTRAST AGENTS GLOBAL MARKET, BY IMAGING

8.1 INTRODUCTION
8.2 DIAGNOSTIC IMAGING
8.3 INTERVENTIONAL IMAGING

9 CONTRAST AGENT GLOBAL MARKET, BY END-USERS

9.1 INTRODUCTION
9.2 HOSPITAL
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
9.4 OTHER END-USER

10 REGIONAL ANALYSIS

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 THE U.S.
  10.2.2 OTHERS
10.3 EUROPE
  10.3.1 GERMANY
  10.3.2 U.K.
  10.3.3 FRANCE
  10.3.4 OTHERS
10.4 ASIA-PACIFIC
  10.4.1 JAPAN
  10.4.2 CHINA
  10.4.3 KOREA
  10.4.4 OTHERS
10.5 REST OF THE WORLD
  10.5.1 BRAZIL
  10.5.2 REST OF LATIN AMERICA
  10.5.3 MIDDLE EAST AND OTHERS

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 APPROVALS
11.3 OTHER KEY DEVELOPMENT
11.4 COLLABORATION
11.5 PARTNERSHIP
11.6 AGREEMENT
11.7 NEW PRODUCT LAUNCH

12 MAJOR PLAYER PROFILES

12.1 BAYER GROUP
  12.1.1 OVERVIEW
  12.1.2 FINANCIALS
  12.1.3 PRODUCT PORTFOLIO
  12.1.4 KEY DEVELOPMENTS
  12.1.5 BUSINESS STRATEGY
  12.1.6 SWOT ANALYSIS
12.2 BEIJING BEILU PHARMACEUTICAL CO., LTD
  12.2.1 OVERVIEW
  12.2.2 FINANCIALS
  12.2.3 PRODUCT PORTFOLIO
  12.2.4 KEY DEVELOPMENTS
  12.2.5 BUSINESS STRATEGY
  12.2.6 SWOT ANALYSIS
12.3 BRACCO GROUP
  12.3.1 OVERVIEW
  12.3.2 FINANCIALS
  12.3.3 PRODUCT PORTFOLIO
  12.3.4 KEY DEVELOPMENTS
  12.3.5 BUSINESS STRATEGY
  12.3.6 SWOT ANALYSIS
12.4 DONGKOOK LIFE SCIENCE
  12.4.1 OVERVIEW
  12.4.2 FINANCIALS
  12.4.3 PRODUCT PORTFOLIO
  12.4.4 KEY DEVELOPMENTS
  12.4.5 BUSINESS STRATEGY
  12.4.6 SWOT ANALYSIS
12.5 FUJIFILM HOLDINGS CORPORATION
  12.5.1 OVERVIEW
  12.5.2 FINANCIALS
  12.5.3 PRODUCT PORTFOLIO
  12.5.4 KEY DEVELOPMENTS
  12.5.5 BUSINESS STRATEGY
  12.5.6 SWOT ANALYSIS
12.6 FUJIPHARMA CO LTD
  12.6.1 OVERVIEW
  12.6.2 FINANCIALS
  12.6.3 PRODUCT PORTFOLIO
  12.6.4 KEY DEVELOPMENTS
  12.6.5 BUSINESS STRATEGY
  12.6.6 SWOT ANALYSIS
12.7 GE COMPANY (GE HEALTHCARE)
  12.7.1 OVERVIEW
  12.7.2 FINANCIALS
  12.7.3 PRODUCT PORTFOLIO
  12.7.4 KEY DEVELOPMENTS
  12.7.5 BUSINESS STRATEGY
  12.7.6 SWOT ANALYSIS
12.8 GUERBET
  12.8.1 OVERVIEW
  12.8.2 FINANCIALS
  12.8.3 PRODUCT PORTFOLIO
  12.8.4 KEY DEVELOPMENTS
  12.8.5 BUSINESS STRATEGY
  12.8.6 SWOT ANALYSIS
12.9 LANTHEUS MEDICAL IMAGING INC.
  12.9.1 OVERVIEW
  12.9.2 FINANCIALS
  12.9.3 PRODUCT PORTFOLIO
  12.9.4 KEY DEVELOPMENTS
  12.9.5 BUSINESS STRATEGY
  12.9.6 SWOT ANALYSIS
12.10 SANOCHEMIA PHARMACEUTICAL AG
  12.10.1 OVERVIEW
  12.10.2 FINANCIALS
  12.10.3 PRODUCT PORTFOLIO
  12.10.4 KEY DEVELOPMENTS
  12.10.5 BUSINESS STRATEGY
  12.10.6 SWOT ANALYSIS
12.11 TAEJOON PHARM CO., LTD
  12.11.1 OVERVIEW
  12.11.2 FINANCIALS
  12.11.3 PRODUCT PORTFOLIO
  12.11.4 KEY DEVELOPMENTS
  12.11.5 BUSINESS STRATEGY
  12.11.6 SWOT ANALYSIS

LIST OF TABLES

TABLE 1 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 2 MRI CONTRAST AGENT GLOBAL CONSUMPTION, (2017-2025) (L)
TABLE 3 X-RAY/CT CONTRAST AGENT GLOBAL CONSUMPTION, (2017-2025) (L)
TABLE 4 CONTRAST AGENT GLOBAL MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
TABLE 5 IODINE BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 6 IODINE BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 7 IODINE BASED IONIC CONTRAST AGENT GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 8 IODINE BASED IONIC CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 9 IODINE BASED IONIC MONOMER CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 10 IODINE BASED IONIC DIMER CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 11 IODINE BASED NON-IONIC CONTRAST AGENT GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 12 IODINE BASED NON-IONIC CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 13 IODINE BASED NON-IONIC MONOMER CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 14 IODINE BASED NON-IONIC DIMER CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 15 GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 16 GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 17 MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 18 MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 19 MACROCYCLIC IONIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 20 MACROCYCLIC NON-IONIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 21 LINEAR GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 22 LINEAR GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 23 LINEAR IONIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 24 LINEAR NON-IONIC GADOLINIUM-BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 25 MICROBUBBLE BASED CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 26 OTHER CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 27 CONTRAST AGENT GLOBAL MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
TABLE 28 X-RAY/CT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 29 MAGNETIC RESONANCE IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 30 ULTRASOUND GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 31 CONTRAST AGENT GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 32 CARDIOVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 33 CANCER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 34 GASTROINTESTINAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 35 MUSCULOSKELETAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 36 NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 37 NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 38 OBSTETRICS AND GYNECOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 39 UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 40 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 41 CONTRAST AGENT GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
TABLE 42 INTRAVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 43 ORAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 44 RECTAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 45 OTHER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 46 CONTRAST AGENT GLOBAL MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
TABLE 47 DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 48 INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 49 CONTRAST AGENT GLOBAL MARKET REVENUE, BY END-USERS, (2017-2025) ($MN)
TABLE 50 CONTRAST AGENT HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 51 CONTRAST AGENT DIAGNOSTIC & AMBULATORY SURGICAL CENTER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 52 OTHER END-USERS CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 53 CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
TABLE 54 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
TABLE 55 NORTH AMERICA IODINE BASED CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 56 NORTH AMERICA IODINE BASED IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 57 NORTH AMERICA IODINE BASED NON-IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 58 NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 59 NORTH AMERICA MACROCYCLIC CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 60 NORTH AMERICA LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 61 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
TABLE 62 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 63 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
TABLE 64 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
TABLE 65 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
TABLE 66 NORTH AMERICA CONTRAST AGENT GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 67 EUROPE CONTRAST AGENT MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
TABLE 68 EUROPE IODINE BASED CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 69 EUROPE IODINE BASED IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 70 EUROPE IODINE BASED NON-IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 71 EUROPE GADOLINIUM-BASED CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 72 EUROPE MACROCYCLIC CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 73 EUROPE LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 74 EUROPE CONTRAST AGENT MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
TABLE 75 EUROPE CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 76 EUROPE CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
TABLE 77 EUROPE CONTRAST AGENT MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
TABLE 78 EUROPE CONTRAST AGENT MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
TABLE 79 EUROPE CONTRAST AGENT GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 80 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
TABLE 81 ASIA-PACIFIC IODINE BASED CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 82 ASIA-PACIFIC IODINE BASED IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 83 ASIA-PACIFIC IODINE BASED NON-IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 84 ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 85 ASIA-PACIFIC MACROCYCLIC CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 86 ASIA-PACIFIC LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 87 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
TABLE 88 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 89 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
TABLE 90 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
TABLE 91 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
TABLE 92 ASIA-PACIFIC CONTRAST AGENT GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 93 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
TABLE 94 REST OF THE WORLD IODINE BASED CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 95 REST OF THE WORLD IODINE BASED IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 96 REST OF THE WORLD IODINE BASED NON-IONIC CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 97 REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENT MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
TABLE 98 REST OF THE WORLD MACROCYCLIC CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 99 REST OF THE WORLD LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
TABLE 100 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
TABLE 101 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
TABLE 102 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
TABLE 103 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
TABLE 104 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
TABLE 105 REST OF THE WORLD CONTRAST AGENT GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
TABLE 106 APPROVALS (2016-2018)
TABLE 107 OTHER KEY DEVELOPMENT, (2016-2018)
TABLE 108 COLLABORATION, (2016-2018)
TABLE 109 PARTNERSHIP, (2016-2018)
TABLE 110 AGREEMENT, (2016-2018)
TABLE 111 NEW PRODUCT LAUNCH, (2016-2018)
TABLE 112 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
TABLE 113 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
TABLE 114 BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
TABLE 115 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016 – 2018) ($MN)
TABLE 116 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
TABLE 117 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2016 – 2018) ($BN)
TABLE 118 FUJIPHARMA CO LTD: TOTAL REVENUE AND R&D EXPENSES, (2016–2018) ($MN)
TABLE 119 FUJIPHARMA CO LTD: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
TABLE 120 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2016 – 2018) ($MN)
TABLE 121 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
TABLE 122 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2016 –2018) ($MN)
TABLE 123 GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
TABLE 124 GUERBET: SEGMENTAL REVENUE (2015-2017) ($MN)
TABLE 125 GUERBET: GEOGRAPHIC REVENUE (2015-2017) ($MN)
TABLE 126 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 127 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2016-2018) ($MN)
TABLE 128 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
TABLE 129 SANOCHEMIA PHARMACEUTICAL AG: TOTAL REVENUE
AND R&D EXPENSES (2016-2018) ($MN)
TABLE 130 SANOCHEMIA PHARMACEUTICAL AG: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)

LIST OF FIGURES

FIGURE 1 CONTRAST AGENT GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2017-2025) ($MN), 2018 (%)
FIGURE 2 RESEARCH METHODOLOGY: CONTRAST AGENT GLOBAL MARKET
FIGURE 3 CONTRAST AGENT GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 CONTRAST AGENTS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 CONTRAST AGENT GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 CONTRAST AGENT GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 CONTRAST AGENTS GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2013–2018)
FIGURE 9 CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 10 CONTRAST AGENT MARKET: PORTER’S ANALYSIS
FIGURE 11 CONTRAST AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
FIGURE 12 X-RAY/CT CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2018) (%)
FIGURE 13 MRI CONTRAST AGENT MARKET: MAJOR PLAYER ANALYSIS (2018) (%)
FIGURE 14 ULTRASOUND BASED CONTRAST AGENT: MAJOR PLAYER ANALYSIS (2018) (%)
FIGURE 15 REGIONAL AND COUNTRYWISE CONSUMPTION OF MRI CONTRAST AGENT IN SHARE AND LITERS: (2018)(%)(L)
FIGURE 16 REGIONAL AND COUNTRYWISE CONSUMPTION OF X-RAY/CT CONTRAST AGENT IN SHARE AND LITERS: (2018) (%) (L)
FIGURE 17 CONTRAST AGENTS GLOBAL MARKET SHARE, BY MOLECULE (2018 V/S 2025) (%)
FIGURE 18 IODINE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY IONICITY (2018 V/S 2025) (%)
FIGURE 19 IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 20 IODINE BASED IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 21 IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY CHEMICAL STRUCTURE (2018 V/S 2025) (%)
FIGURE 22 IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 23 IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 24 GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE (2017-2025) ($MN)
FIGURE 25 GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 26 LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 27 MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 28 OTHER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 29 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MODALITY (2017-2025) ($MN)
FIGURE 30 CONTRAST AGENTS GLOBAL MARKET SHARE, BY APPLICATION (2018) (%)
FIGURE 31 CARDIOVASCULAR GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 32 GASTROINTESTINAL GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 33 MUSCULOSKELETAL GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 34 NEPHROLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 35 OBSTETRICS AND GYNECOLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 36 UROLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 37 OTHER APPLICATIONS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 38 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2018) ($MN)
FIGURE 39 INTRAVASCULAR GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 40 ORAL GLOBAL MARKET REVENUE, BY REGION (2018-2025) ($MN)
FIGURE 41 RECTAL GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
FIGURE 42 OTHER GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
FIGURE 43 CONTRAST AGENT GLOBAL MARKET SHARE, BY IMAGING (2018 V/S 2025) (%)
FIGURE 44 DIAGNOSTIC IMAGING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
FIGURE 45 INTERVENTIONAL IMAGING PROCEDURAL SHARE (%)
FIGURE 46 CONTRAST AGENT GLOBAL MARKET SHARE, BY END-USERS, (2018 V/S 2025) (%)
FIGURE 47 HOSPITAL GLOBAL MARKET SHARE, BY END-USERS, (2018 V/S 2025) (%)
FIGURE 48 DIAGNOSTIC & AMBULATORY SURGICAL CENTER GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 49 OTHER END-USER GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
FIGURE 50 CONTRAST AGENT GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN), CAGR (%)
FIGURE 51 CONTRAST AGENT GLOBAL MARKET SHARE, BY REGION AND COUNTRY (2018) (%)
FIGURE 52 NORTH AMERICA CONTRAST AGENT MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENT MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
FIGURE 53 NORTH AMERICA IODINE BASED IONIC AND NON-IONIC CONTRAST AGENT MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
FIGURE 54 NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENT MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
FIGURE 55 NORTH AMERICA CONTRAST AGENT MARKET SHARE, BY MODALITY, AND CONTRAST AGENT MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
FIGURE 56 NORTH AMERICA CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 57 NORTH AMERICA CONTRAST AGENT MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
FIGURE 58 NORTH AMERICA CONTRAST AGENT MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
FIGURE 59 U.S. CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 60 U.S. CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 61 U.S. CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 62 U.S. CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 63 OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 64 OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 65 OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 66 OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 67 EUROPE CONTRAST AGENT MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENT MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
FIGURE 68 EUROPE IODINE BASED IONIC AND NON-IONIC CONTRAST AGENT MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
FIGURE 69 EUROPE GADOLINIUM-BASED CONTRAST AGENT MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
FIGURE 70 EUROPE CONTRAST AGENT MARKET SHARE, BY MODALITY, AND CONTRAST AGENT MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
FIGURE 71 EUROPE CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 72 EUROPE CONTRAST AGENT MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
FIGURE 73 EUROPE CONTRAST AGENT MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
FIGURE 74 GERMANY CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 75 GERMANY CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 76 GERMANY CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 77 GERMANY CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 78 U.K. CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 79 U.K. CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 80 U.K. CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 81 U.K. CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 82 FRANCE CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 83 FRANCE CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 84 FRANCE CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 85 FRANCE CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 86 OTHER EUROPEAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 87 OTHER EUROPEAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 88 OTHER EUROPEAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 89 OTHER EUROPEAN COUNTRIES CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 90 ASIA-PACIFIC CONTRAST AGENT MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENT MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
FIGURE 91 ASIA-PACIFIC IODINE BASED IONIC AND NON-IONIC CONTRAST AGENT MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
FIGURE 92 ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENT MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
FIGURE 93 ASIA-PACIFIC CONTRAST AGENT MARKET SHARE, BY MODALITY, AND CONTRAST AGENT MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
FIGURE 94 ASIA-PACIFIC CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 95 ASIA-PACIFIC CONTRAST AGENT MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
FIGURE 96 ASIA-PACIFIC CONTRAST AGENT MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
FIGURE 97 JAPAN CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 98 JAPAN CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 99 JAPAN CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 100 JAPAN CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 101 CHINA CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 102 CHINA CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 103 CHINA CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 104 CHINA CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 105 KOREA CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 106 KOREA CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 107 KOREA CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 108 KOREA CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 109 OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 110 OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 111 OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 112 OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 113 REST OF THE WORLD CONTRAST AGENT MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENT MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
FIGURE 114 REST OF THE WORLD IODINE BASED IONIC AND NON-IONIC CONTRAST AGENT MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
FIGURE 115 REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENT MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENT MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
FIGURE 116 REST OF THE WORLD CONTRAST AGENT MARKET SHARE, BY MODALITY, AND CONTRAST AGENT MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
FIGURE 117 REST OF THE WORLD CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 118 REST OF THE WORLD CONTRAST AGENT MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
FIGURE 119 REST OF THE WORLD CONTRAST AGENT MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
FIGURE 120 BRAZIL CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 121 BRAZIL CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 122 BRAZIL CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 123 BRAZIL CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 124 REST OF LATAM CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 125 REST OF LATAM CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 126 REST OF LATAM CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 127 REST OF LATAM CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 128 MIDDLE EAST AND OTHERS CONTRAST AGENT MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
FIGURE 129 MIDDLE EAST AND OTHERS CONTRAST AGENT MARKET REVENUE, BY APPLICATION, (2018) ($MN)
FIGURE 130 MIDDLE EAST AND OTHERS CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
FIGURE 131 MIDDLE EAST AND OTHERS CONTRAST AGENT MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
FIGURE 132 KEY GROWTH STRATEGIES (2016 – 2018)
FIGURE 133 SWOT: BAYER GROUP
FIGURE 134 SWOT: BEIJING BEILU PHARMACEUTICAL CO., LTD.
FIGURE 135 SWOT: BRACCO GROUP
FIGURE 136 SWOT: DONGKOOK LIFE SCIENCE
FIGURE 137 SWOT: FUJIFILM HOLDING CORPORATION
FIGURE 138 SWOT: FUJIPHARMA CO LTD
FIGURE 139 SWOT: GE HEALTHCARE
FIGURE 140 SWOT: GUERBET
FIGURE 141 SWOT: LANTHEUS MEDICAL IMAGING INC.
FIGURE 142 SWOT: SANOCHEMIA PHARMACEUTICAL AG
FIGURE 143 SWOT: TAEJOON PHARM CO., LTD.


More Publications